CD71/CD44 dual-aptamer-gemcitabine conjugate for tumor co-targeting treatment of bladder cancer

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Liu, Biao;Wang, Jinrong;Peng, Yongbo;Zeng, Hongliang;Zhang, Qun;...

作者机构：

[Wang, Jinrong; Liu, Jiahao; Hu, Xing; Liu, Jianye; Tang, Jin; Hou, Weibin; Xiang, Wei; Wang, Long; Long, Zhi; Liu, Biao] Cent South Univ, Dept Urol, Xiangya Hosp 3, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.

[Peng, Yongbo] Chongqing Med Univ, Coll Pharm, Chongqing Key Lab Pharmaceut Metab Res, Key Lab Biochem & Mol Pharmacol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.

[Zeng, Hongliang] Hunan Acad Chinese Med, Ctr Med Lab Anim, Changsha 410013, Hunan, Peoples R China.

[Zhang, Qun] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Radiotherapy, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.

[Deng, Minhua] Sun Yat Sen Univ, Dept Urol, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.

语种：

英文

关键词：

Dual-aptamer;Cancer stem cells;Targeted therapy;Drug delivery

期刊：

Chemical Engineering Journal

ISSN：

1385-8947

年：

2023

卷：

464

页码：

142597

DOI：

10.1016/j.cej.2023.142597

基金类别：

Huxiang Young Talents Plan Project of Hunan Province [2019RS2015]; Natural Science Foundation of Hunan Province [2023JJ10092]; Wisdom Accumulation and Talent Cultivation Project of the Third xiangya hospital of Central South University [mnzl202030]; Beijing Bethune Charitable Foundation; [YX202204]

机构署名：

本校为其他机构

摘要：

Conventional chemotherapy lacks the ability to specifically target cancer cells, thus although it eliminates tumor tissues to some extent, it also damages normal tissues and organs. Meanwhile, cancer stem cells (CSCs)-induced tumor regrowth and drug resistance limits the application of some chemotherapy drugs. In this study, the CD71/ CD44 dual-aptamer-gemcitabine (CD71-CD44-GEMs) conjugate was designed to treat bladder cancer through the co-targeting by CD71 of bladder cancer cells and by CD44 of bladder CSCs. A series of studies were used to evaluate the binding specificity and the in vitro ...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

CD71/CD44 dual-aptamer-gemcitabine conjugate for tumor co-targeting treatment of bladder cancer

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问